var data={"title":"Zinc acetate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Zinc acetate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/148721?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=zinc-acetate-drug-information\" class=\"drug drug_general\">see &quot;Zinc acetate: Drug information&quot;</a> and <a href=\"topic.htm?path=zinc-acetate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Zinc acetate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9831430\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Galzin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16229020\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Trace Element</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16229028\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=zinc-acetate-drug-information\" class=\"drug drug_general\">see &quot;Zinc acetate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dose expressed in mg <b>elemental</b> zinc</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Wilson disease:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: Children &ge;10 years and Adolescents: Oral: 25 mg 3 times daily; may increase to 50 mg 3 times daily if inadequate response to lower dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AASLD recommendations (Roberts 2008): <b>Note:</b> Three times daily dosing recommended; doses must be administered at least twice daily to be effective:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;5 years and &lt;50 kg: Limited data available: Oral: 25 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;50 kg and Adolescents: Oral: 50 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Wilson disease:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Males and nonpregnant females: Oral: 50 mg 3 times daily; may administer 25 mg 3 times daily if patient is compliant with therapy (increase dose to 50 mg 3 times daily if inadequate response to lower dose)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pregnant females: Oral: 25 mg 3 times daily; may increase to 50 mg 3 times daily if inadequate response to lower dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9850352\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Galzin: 25 mg, 50 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9882124\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21963758\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=zinc-acetate-drug-information\" class=\"drug drug_general\">see &quot;Zinc acetate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Strength of Galzin capsule is expressed as elemental zinc.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16229029\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer on empty stomach at least 1 hour before or 2 to 3 hours after meals, and 1 hour away from beverages other than water. Gastric irritation most commonly associated with morning dose; may administer 1 hour after breakfast if gastric irritation occurs. Swallow capsule whole; do not chew or open.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9850332\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions permitted  to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16229021\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Maintenance treatment of Wilson&rsquo;s disease following initial chelation therapy (FDA approved in ages &ge;10 years and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9850328\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Neurological deterioration (uncommon)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Gastric irritation, increased serum amylase, increased serum lipase</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum alkaline phosphatase</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Hepatic insufficiency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9850302\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to zinc acetate or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9850324\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Central nervous system: Neurological deterioration may occur with initial therapy as copper stores are mobilized; effects are less common when compared to chelation therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI effects: Gastric irritation/upset may occur with use and particularly with the  morning dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Not recommended for initial treatment of Wilson disease in symptomatic patients; may be used as maintenance therapy after patient has been stabilized on initial chelation therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Therapy management: Hepatic copper levels should not be used to manage therapy  as they do not differentiate between potentially toxic free copper and safely bound copper.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300235\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9922728\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=88572&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ceftibuten: Zinc Salts may decrease the serum concentration of Ceftibuten.  Management: Consider administering oral zinc salts at least 3 hours after ceftibuten.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalexin: Zinc Salts may decrease the absorption of Cephalexin.  Management: Consider administering oral zinc salts at least 3 hours after cephalexin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Zinc Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dolutegravir: Zinc Salts may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after oral zinc salts. Administer the dolutegravir/rilpivirine combination product at least 4 hours before or 6 hours after oral zinc salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag: Zinc Salts may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any zinc-containing product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Zinc Salts may decrease the serum concentration of Quinolones.  Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for levo-, nor-, pe- or ofloxacin or nalidixic acid) oral zinc salts.<b> Exceptions: </b>LevoFLOXacin (Oral Inhalation).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: Zinc Salts may decrease the absorption of Tetracyclines. Only a concern when both products are administered orally.  Management: Consider doxycycline as a noninteracting tetracycline derivative. Separate dose administration of oral tetracycline derivative and oral zinc salts by at least 2 hours to minimize interaction.<b> Exceptions: </b>Doxycycline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trientine: May decrease the serum concentration of Zinc Salts. Zinc Salts may decrease the serum concentration of Trientine.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9850330\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food and beverages other than water may interfere with zinc absorption. Management: Administer on empty stomach at least 1 hour before or 2 to 3 hours after meals and at least 1 hour separated from beverages other than water. Gastric irritation is most commonly associated with morning dose; may administer morning dose between breakfast and lunch if GI irritation occurs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9850298\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">A (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9850299\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adequate, well-controlled studies in pregnant women have not shown an increased risk of fetal abnormalities. The risk of fetal harm appears remote with use of zinc acetate during pregnancy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16229030\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum non-ceruloplasmin bound copper, 24-hour urinary copper excretion, 24-hour urinary zinc levels, LFTs, iron and/or other trace minerals, neurologic evaluation including speech, periodic ophthalmic exam </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16229031\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Target ranges for patients with Wilson disease on zinc acetate therapy:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">24-hour urinary copper excretion: &le;75 mcg/24 hours (patients on chelation therapy will have increased urinary copper due to chelated copper)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Non-ceruloplasmin plasma copper (free copper): &lt;20 mcg/dL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9850344\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Zinc induces production of the copper binding protein metallothionein in enterocytes. Copper binding within enterocytes results in an impairment of the intestinal absorption of dietary copper and reabsorption of endogenously secreted copper in saliva, bile, gastric acid.  Following enterocyte desquamation, bound copper is eliminated in the feces.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9850333\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Small intestine (IOM 2001); impaired with food and beverages (other than water)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Stored primarily in skeletal muscle and bone (IOM 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Primarily to albumin (IOM 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces and urine (IOM 2001)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322803\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Galzin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (250): $408.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (250): $680.59</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12707705\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Corznc (LK);</li>\n      <li>Galzin (AR);</li>\n      <li>Nobelzin (JP, KR);</li>\n      <li>Wilzin (AT, BE, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, HR, IE, IS, IT, LT, MT, NL, PL, PT, RO, RU, SE, SI, SK, TR, TW);</li>\n      <li>Zevac (LK);</li>\n      <li>Zinca (TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Anderson LA, Hakojarvi SL, Boudreaux SK. Zinc acetate treatment in Wilson's disease. <i>Ann Pharmacother</i>. 1998;32(1):78-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zinc-acetate-pediatric-drug-information/abstract-text/9475826/pubmed\" target=\"_blank\" id=\"9475826\">9475826</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Galzin (zinc acetate) [prescribing information]. North Wales, PA: Teva Pharmaceuticals; February 2016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zinc-acetate-pediatric-drug-information/abstract-text/9475826/pubmed\" target=\"_blank\" id=\"9475826\">9475826</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc</i>, Washington, DC: National Academy Press, 2001. Available at <a href=\"http://www.nal.usda.gov/fnic/DRI//DRI_Vitamin_A/vitamin_a_full_report.pdf\">http://www.nal.usda.gov/fnic/DRI//DRI_Vitamin_A/vitamin_a_full_report.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: an update. American Association for Study of Liver Diseases (AASLD). <i>Hepatology</i>. 2008;47(6):2089-2111.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zinc-acetate-pediatric-drug-information/abstract-text/18506894/pubmed\" target=\"_blank\" id=\"18506894\">18506894</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 88572 Version 75.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9831430\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F16229020\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F16229028\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9850352\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F9882124\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21963758\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F16229029\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F9850332\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F16229021\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9850328\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9850302\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9850324\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300235\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9922728\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F9850330\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F9850298\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9850299\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F16229030\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F16229031\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9850344\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F9850333\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322803\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F12707705\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/88572|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=zinc-acetate-drug-information\" class=\"drug drug_general\">Zinc acetate: Drug information</a></li><li><a href=\"topic.htm?path=zinc-acetate-patient-drug-information\" class=\"drug drug_patient\">Zinc acetate: Patient drug information</a></li></ul></div></div>","javascript":null}